# A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus

> **NCT06982859** · PHASE1 · RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 95 (estimated)

## Conditions studied

- Diabetes Mellitus
- Insulin Sensitivity

## Interventions

- **DRUG:** Retatrutide
- **DRUG:** Semaglutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06982859
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-02
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 95 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06982859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06982859, "A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06982859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*